Evidence map›Paper›PMID 36595938›Full record

ArticleSTAR protocols2022

Generation of orthotopic patient-derived xenograft models for pancreatic cancer using tumor slices.

Alvaro Curiel-Garcia, Amanda R Decker-Farrell, Stephen A Sastra, Kenneth P Olive

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in STAR protocols, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Alvaro Curiel-GarciaDivision of Digestive and Liver Diseases, Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY 10032, USA; Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY 1032, USA. Electronic address: ac4667@cumc.columbia.edu.
Amanda R Decker-FarrellDivision of Digestive and Liver Diseases, Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY 10032, USA; Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY 1032, USA.
Stephen A SastraDivision of Digestive and Liver Diseases, Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY 10032, USA; Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY 1032, USA.
Kenneth P OliveDivision of Digestive and Liver Diseases, Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY 10032, USA; Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY 1032, USA. Electronic address: kenolive@columbia.edu.

Funding

The Organoid and Cell Culture CoreP30DK132710 · NIDDK · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Peter Alan Sims · 2022 to 2026
$7.2M
Targeting cysteine import to induce ferroptotic cell death in pancreatic cancerR01CA215607 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Kenneth P. Olive · 2017 to 2026
$4.0M
Bacterial Delivery of CXCR7 Nanobodies to Alleviate Immune Suppression in Pancreatic CancerF31CA250443 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI DECKER-FARRELL, AMANDA ROSE · 2020 to 2022
$123k
NCI NIH HHS F31 CA250443NCI NIH HHS R01 CA215607NIDDK NIH HHS P30 DK132710
6 · The paper itself

Abstract

Orthotopic patient-derived xenograft models recapitulate the genomic complexity of the original tumor and some aspects of local microenvironment, useful for rapid development and validation of personalized treatment strategies. Here, we precisely describe a protocol for generating tumor slices from human or murine-derived pancreatic cancer. They are then implanted directly into the murine pancreas, monitored using ultrasound, with a 90% success rate. This assay creates a clinically relevant in vivo model facilitating personalized treatment development.

Indexed as

Pancreatic NeoplasmsAnimalsHeterograftsHumansMicePancreasTumor MicroenvironmentCancerModel Organisms

Identifiers

PMID36595938
PMCPMC9768417

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.